Zynerba Pharmaceuticals (NASDAQ:ZYNE) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, February 4th.
ZYNE has been the topic of several other reports. Cantor Fitzgerald set a $21.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, December 17th. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a report on Saturday, January 19th. Finally, HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, November 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Zynerba Pharmaceuticals currently has an average rating of “Hold” and an average price target of $15.88.
ZYNE stock traded down $0.04 during trading on Monday, hitting $5.15. The stock had a trading volume of 380,921 shares, compared to its average volume of 1,658,812. Zynerba Pharmaceuticals has a twelve month low of $2.75 and a twelve month high of $12.50. The stock has a market cap of $90.25 million, a price-to-earnings ratio of -2.08 and a beta of 4.98.
Hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new stake in shares of Zynerba Pharmaceuticals during the 4th quarter valued at approximately $40,000. Two Sigma Investments LP purchased a new stake in Zynerba Pharmaceuticals in the fourth quarter valued at approximately $120,000. Thompson Siegel & Walmsley LLC purchased a new stake in Zynerba Pharmaceuticals in the third quarter valued at approximately $157,000. Raymond James & Associates purchased a new stake in Zynerba Pharmaceuticals in the second quarter valued at approximately $164,000. Finally, GSA Capital Partners LLP purchased a new stake in Zynerba Pharmaceuticals in the third quarter valued at approximately $177,000. 16.40% of the stock is currently owned by hedge funds and other institutional investors.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Read More: Price-Sales Ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.